StockData

CVRx vs Orchestra BioMed

CVRX and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CVRX and OBIO compare

Orchestra BioMed is the larger company, worth 26 times as much as CVRx ($428M against $16.3M).

Orchestra BioMed grew revenue faster over the last twelve months (986% versus 12.0% for CVRx).

CVRx keeps more of each dollar of sales as profit, with a net margin of −84.9% compared with −185% at Orchestra BioMed.

Orchestra BioMed scores higher on the StockData Score (9 against 8 for CVRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCVRXOBIO
Size and price
Market cap$16.3M$428M
Share price$0.613$7.12
Change, 1 year−93.1%70.3%
Change, 5 years−95.3%−27.8%
Beta (5Y)−0.961.12
Employees22386
StockData Score
Total score89 (better)
Valuation score3 (better)0
Growth score33
Performance score11
Health score15 (better)
Dividend score00
Valuation
P/S0.3× (better)13.4×
P/B0.8×–
FCF yield−251%−13.8% (better)
Fair value$7.09–
Margin of safety91.4%–
Growth
Revenue growth (TTM)12.0%986% (better)
Revenue growth, 5Y average56.4%–
Profitability
Gross margin86.9%99.5% (better)
Operating margin−79.5% (better)−181%
Net margin−84.9% (better)−185%
FCF margin−67.1% (better)−185%
Return on equity−133%–
Return on invested capital−293%–
Financial health
Debt / equity2.94–
Interest coverage−8.1×–
Current ratio8.048.26 (better)
Altman Z-score−9.29−2.31 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield−2.9%–
Shareholder yield−2.9%0.00% (better)
Ownership
Held by institutions57.4%46.1%
Held by insiders49.9%56.6%
Insider net buying, 12 months$247K$6.1M (better)
Short interest, % of float13.6%10.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.